logo-loader
viewGenprex, Inc.

Genprex hires two accomplished life science executives as it advances strategic plan

Catherine M Vaczy becomes executive vice president and chief strategy officer, while Michael T Redman becomes executive vice president and chief operating officer

Genprex, Inc. -
These appointments follow hot on the heels of Genprex receiving fast track designation from the FDA for its lead drug candidate

Genprex Inc (NASDAQ:GNPX) has appointed two experienced life sciences executives as the firm advances its lead drug candidate into key clinical programs and pursues partnerships for its cancer platform and newly licensed gene therapy technology for diabetes.

Catherine M Vaczy becomes executive vice president and chief strategy officer, while Michael T Redman becomes executive vice president and chief operating officer.

READ: Genprex secures $17.5M at-the-market offering to fund Oncoprex drug development

These appointments follow hot on the heels of Genprex receiving fast track designation from the FDA for its lead drug candidate Oncoprex for non-small cell lung cancer, its newly licensed gene therapy for diabetes and a capital raise of over $26 million to support funding its clinical programs.

Rodney Varner,  Genprex CEO, said: "Their combined expertise in business development, corporate strategy, manufacturing, clinical trial strategy and operations and regulatory affairs will be of great value as we build Genprex into a leading gene therapy company bringing new treatment options to patients in need."

"We are fortunate to have raised over $26 million just prior to the current turmoil in the markets, significantly strengthening our balance sheet and well positioning us financially as we execute on our strategic plan," he added. 

Ms Vaczy has over 20 years' experience as a founder and senior executive of life science companies. Her CV includes experiences with NeoStem Inc (now Caladrius Biosciences), a Nasdaq-listed clinical stage biotechnology company and ImClone Systems Incorporated (sold to Eli Lily and Company).

Meanwhile, Redman brings more than 30 years of experience in the life sciences industry. He has held a variety of key executive roles at clinical-stage companies, where he focused on strategic business development and US and worldwide manufacturing and clinical operations, the firm said.

Redman was president, CEO and director of Oncolix Inc, a publicly traded clinical-stage biopharma focused on developing therapies for women’s and children’s cancers.

In 2001, he co-founded Opexa Pharmaceuticals, a company developing immunotherapies for a variety of diseases, and served as its president and CEO until 2005. He has worked at Zonagen (now Repros Therapeutics, which is a part of Allergan), Aronex Pharmaceuticals, Biovail Corporation and American Home Products (acquired by Pfizer).

Contact the author at [email protected]

Quick facts: Genprex, Inc.

Price: 3.11 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $120.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

1 week, 3 days ago

2 min read